Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 3/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469036 | 0.91 | GRM5 (0.54) | GRM5PTGS2MAPK14ALDH1A1POLB | |
| SCHEMBL2472044 | 0.89 | PTGS2 (0.41) | PTGS2MAPK14MAPK13MAPK12MAPK10 | |
| SCHEMBL2468994 | 0.87 | PTGS2 (0.44) | PTGS2MAPK14POLBMAPK13MAPK12 | |
| SCHEMBL2471384 | 0.86 | PTGS2 (0.43) | PTGS2MAPK14POLBMAPK13MAPK12 | |
| SCHEMBL2468784 | 0.85 | PTGS2 (0.41) | PTGS2MAPK14POLBMAPK13MAPK12 | |
| SCHEMBL2469219 | 0.85 | PTGS2 (0.46) | PTGS2MAPK14ALDH1A1POLBMAPK13 | |
| SCHEMBL2473712 | 0.84 | PTGS2 (0.48) | PTGS2MAPK14POLBMAPK13MAPK12 | |
| SCHEMBL2473626 | 0.83 | MAPT (0.43) | PTGS2MAPK14POLBMAPK13MAPK12 | |
| SCHEMBL2473287 | 0.82 | PTGS2 (0.46) | GRM5PTGS2MAPK14POLBMAPK13 | |
| SCHEMBL2476849 | 0.81 | PTGS2 (0.48) | PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | claimed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | claimed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | claimed |
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | GABRA5, GABRA4, GABRA1 | GRM5 26/4885PTGS2 3762/4885MAPK14 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.